Abstract
Megakaryoblastic leukemia 1 (MKL1) promotes the regulation of essential cell processes, including actin cytoskeletal dynamics, by coactivating serum response factor. Recently, the first human with MKL1 deficiency, leading to a novel primary immunodeficiency, was identified. We report a second family with 2 siblings with a homozygous frameshift mutation in MKL1. The index case died as an infant from progressive and severe pneumonia caused by Pseudomonas aeruginosa and poor wound healing. The younger sibling was preemptively transplanted shortly after birth. The immunodeficiency was marked by a pronounced actin polymerization defect and a strongly reduced motility and chemotactic response by MKL1-deficient neutrophils. In addition to the lack of MKL1, subsequent proteomic and transcriptomic analyses of patient neutrophils revealed actin and several actin-related proteins to be downregulated, confirming a role for MKL1 as a transcriptional coregulator. Degranulation was enhanced upon suboptimal neutrophil activation, whereas production of reactive oxygen species was normal. Neutrophil adhesion was intact but without proper spreading. The latter could explain the observed failure in firm adherence and transendothelial migration under flow conditions. No apparent defect in phagocytosis or bacterial killing was found. Also, monocyte-derived macrophages showed intact phagocytosis, and lymphocyte counts and proliferative capacity were normal. Nonhematopoietic primary fibroblasts demonstrated defective differentiation into myofibroblasts but normal migration and F-actin content, most likely as a result of compensatory mechanisms of MKL2, which is not expressed in neutrophils. Our findings extend current insight into the severe immune dysfunction in MKL1 deficiency, with cytoskeletal dysfunction and defective extravasation of neutrophils as the most prominent features.
Original language | English |
---|---|
Pages (from-to) | 2171-2181 |
Number of pages | 11 |
Journal | Blood |
Volume | 135 |
Issue number | 24 |
Early online date | 3 Mar 2020 |
DOIs | |
Publication status | Published - 11 Jun 2020 |
Externally published | Yes |
Funding
This study was funded, in part, by the European Union’s Horizon 2020 Research and Innovation Program under Grant Agreement No.668303, Program on Prevention Outcomes Practices Grant PPOP-12-001, the Center of Immunodeficiencies Amsterdam Grant CIDA-2015, and the E-Rare ZonMW grant 90030376506.
Funders | Funder number |
---|---|
E-Rare ZonMW | 90030376506 |
Horizon 2020 Framework Programme | PPOP-12-001, 668303, CIDA-2015 |